Exercise of over-allotment option and end of the stabilization period


Carnegie Investment Bank AB (publ) (“Carnegie”) and ABG Sundal Collier AB (“ABGSC”) exercise the over-allotment option regarding 2,043,966 shares in BONESUPPORT HOLDING AB (publ) (“BONESUPPORT” or the “Company”) and notifies that stabilization measures have been undertaken in the Company’s shares on Nasdaq Stockholm. The stabilization period has now ended and no further stabilization transaction will be effected.

As announced in connection with the offering to acquire newly issued shares in the Company and the listing of the Company’s shares on Nasdaq Stockholm (the ”Offering”), Carnegie and ABGSC may, acting as Joint Global Coordinators, carry out transactions aimed at supporting the market price of the shares at levels above those which might otherwise prevail in the open market.

Stabilization transactions may be undertaken on Nasdaq Stockholm, in the over-the-counter market or otherwise, at any time during the period starting on the date of commencement of trading in the shares on Nasdaq Stockholm and ending no later than 30 calendar days thereafter. Joint Global Coordinators are, however, not required to undertake any stabilization and there is no assurance that stabilization will be undertaken. Stabilization, if undertaken, may be discontinued at any time without prior notice. In no event will transactions be effected at levels above the price in the Offering.

The board of directors of the Company has granted Joint Global Coordinators an over-allotment option, which may be utilized in whole or in part for 30 days from the first date of trading in the Company’s shares on Nasdaq Stockholm, to issue up to 2,586,206 additional shares, corresponding to up to 15 percent of the total number of shares encompassed by the Offering, at a price corresponding to the price in the Offering, i.e. 29 SEK, to cover any over-allotment in connection with the Offering (the “Over-allotment option”). The Joint Global Coordinators now notify that the over-allotment option with respect to 2,043,966 shares has been exercised. The Company will thereby be provided with additionally approximately SEK 55 million, which means that the Company has been provided with approximately SEK 516 million as a result of the Offering, after issue expenses. Immediately following registration of the new shares issued pursuant to the Over-allotment option, the number of shares and votes in the Company will amount to 49,138,735. All shares in the Company that the Joint Global Coordinators have borrowed from Stiftelsen Industrifonden with the purpose of covering the over-allotment in the Offering will be returned within short. Following the exercise of the Over-allotment option, Stiftelsen Industrifonden and Lundbeckfond Invest A/S holds 4,787,806 shares in BONESUPPORT respectively, corresponding to approximately 9.7 percent respectively of the total shares outstanding in the Company. Due to the new share issue, Stiftelsen Industrifonden and Lundbeckfond Invest A/S have noted that their respective ownership will passively go below 10 percent.

Carnegie has, in its capacity as stabilization manager, notified that stabilization measures has been undertaken, in accordance with article 5(4) in the Market Abuse Regulation 596/2014, on Nasdaq Stockholm as specified below. The contact person at Carnegie is Anna Boqvist (tel: +46 8 588 688 00).

Stabilization information:
Securities:Shares (SE0009858152)
Offering size:17 241 379
Offer price:29 SEK
Stabilization manager:Carnegie Investment Bank AB (publ)


Stabilization transactions:
DateQuantityPrice (highest)Price (lowest)Price (volume weighted average)CurrencyTrading venue
2017-07-1819,67829,0029,0029,00SEKNasdaq Stockholm
2017-07-1933,17329,0029,0029,00SEKNasdaq Stockholm
2017-07-2026,64629,0029,0029,00SEKNasdaq Stockholm
2017-07-2119,18129,0029,0029,00SEKNasdaq Stockholm

The stabilization period regarding the Offering has now ended and no further stabilization transactions will be effected. Specified below is a summary of the stabilization transactions which have been effected during the stabilization period in accordance with this press release and the press releases as of 5 July and 17 July 2017, respectively. All transactions during the stabilization period have been effected on Nasdaq Stockholm and no stabilization transactions have been effected on other dates than those specified below.

Stabilization transactions:
DateQuantityPrice (highest)Price (lowest)Price (volume weighted average)CurrencyTrading venue
2017-06-2686,73929,0029,0029,00SEKNasdaq Stockholm
2017-06-2735,20029,0029,0029,00SEKNasdaq Stockholm
2017-06-28228,61929,0028,5028,89SEKNasdaq Stockholm
2017-06-294,09828,6028,5028,55SEKNasdaq Stockholm
2017-06-3014,49428,7028,5028,53SEKNasdaq Stockholm
2017-07-0367828,5028,5028,50SEKNasdaq Stockholm
2017-07-045,65828,5028,5028,50SEKNasdaq Stockholm
2017-07-054,87128,5028,5028,50SEKNasdaq Stockholm
2017-07-0617,81628,5028,5028,50SEKNasdaq Stockholm
2017-07-076,70828,5028,5028,50SEKNasdaq Stockholm
2017-07-1022,45128,5028,5028,50SEKNasdaq Stockholm
2017-07-1112,41428,6028,5028,54SEKNasdaq Stockholm
2017-07-121,77528,5028,5028,50SEKNasdaq Stockholm
2017-07-132,04128,6028,6028,60SEKNasdaq Stockholm
2017-07-1819,67829,0029,0029,00SEKNasdaq Stockholm
2017-07-1933,17329,0029,0029,00SEKNasdaq Stockholm
2017-07-2026,64629,0029,0029,00SEKNasdaq Stockholm
2017-07-2119,18129,0029,0029,00SEKNasdaq Stockholm

This information is information that BONESUPPORT HOLDING AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out below, at 19:30 CET on 21 July 2017.


BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bioceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void. BONESUPPORT’s marketed synthetic bone graft substitutes CERAMENT™ BONE VOID FILLER (BVF), CERAMENT™ G and CERAMENT™ V* are all based on the Company’s novel and proprietary CERAMENT technology platform.

The Company’s products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot. The Company’s research and development is focused on the continuing development and refinement of its existing technology to extend its use into additional indications by the elution of other drugs and therapeutic agents.

BONESUPPORT’s products are based on an innovative technology backed by an intellectual property portfolio of approximately 100 registered and/or pending patents. BONESUPPORT has a nine year track record of safety and efficacy in treating patients with an estimated number of 30,000 procedures performed to date with its products worldwide based on sales data.

BONESUPPORT’s total sales increased from SEK 41 million in 2014 to SEK 105 million in 2016, representing a compound annual growth rate of 60 percent.

The Company’s financial target is to achieve revenue exceeding SEK 500 million in the financial year 2020, with a gross margin exceeding 85 percent and a positive operating profit.

For more information contact:

Richard Davies, CEO, Tel: +46 (0) 46 286 53 71, Email: richard.davies@bonesupport.com

Björn Westberg, CFO, Tel: +46 (0) 46 286 53 60, Email: bjorn.westberg@bonesupport.com

Important information

This announcement is not and does not form a part of any offer for sale of securities.

Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada, Japan or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States.

The offering of securities referred to in this announcement has been made by means of a prospectus. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus.

*CERAMENT G: Not available in the United States, for investigational use only. CERAMENT V: Not available in the United States.


Brain stimulation to relieve symptoms of Parkinson’s disease
25. January 2021
Mini-Brains to shed light on nervous disorders
25. January 2021
Mechanisms of schizophrenia
25. January 2021


Lundbeckfonden Ventures

Lundbeckfonden Emerge